Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
- PMID: 28636769
- DOI: 10.1002/da.22664
Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Abstract
Anxiety and related disorders are the most common mental conditions affecting the North American population. Despite their established efficacy, first-line antidepressant treatments are associated with significant side effects, leading many afflicted individuals to seek alternative treatments. Cannabis is commonly viewed as a natural alternative for a variety of medical and mental health conditions. Currently, anxiety ranks among the top five medical symptoms for which North Americans report using medical marijuana. However, upon careful review of the extant treatment literature, the anxiolytic effects of cannabis in clinical populations are surprisingly not well-documented. The effects of cannabis on anxiety and mood symptoms have been examined in healthy populations and in several small studies of synthetic cannabinoid agents but there are currently no studies which have examined the effects of the cannabis plant on anxiety and related disorders. In light of the rapidly shifting landscape regarding the legalization of cannabis for medical and recreational purposes, it is important to highlight the significant disconnect between the scientific literature, public opinion, and related policies. The aim of this article is to provide a comprehensive review of the current cannabis treatment literature, and to identify the potential for cannabis to be used as a therapeutic intervention for anxiety, mood, and related disorders. Searches of five electronic databases were conducted (PubMed, MEDLINE, Web of Science, PsychINFO, and Google Scholar), with the most recent in February 2017. The effects of cannabis on healthy populations and clinical psychiatric samples will be discussed, focusing primarily on anxiety and mood disorders.
Keywords: anxiety disorders; cannabis treatment; depression; endocannabinoids; marijuana.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Cannabis and mental illness: a review.Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):107-120. doi: 10.1007/s00406-018-0970-7. Epub 2018 Dec 19. Eur Arch Psychiatry Clin Neurosci. 2019. PMID: 30564886 Free PMC article. Review.
-
The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.Depress Anxiety. 2008;25(2):91-7. doi: 10.1002/da.20279. Depress Anxiety. 2008. PMID: 17311265
-
Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users.J Psychiatr Res. 2019 Apr;111:134-139. doi: 10.1016/j.jpsychires.2019.01.024. Epub 2019 Jan 31. J Psychiatr Res. 2019. PMID: 30738930
-
Cannabis and psychiatric disorders: it is not only addiction.Addict Biol. 2008 Jun;13(2):264-75. doi: 10.1111/j.1369-1600.2008.00106.x. Addict Biol. 2008. PMID: 18482435 Review.
-
Pharmacotherapy of comorbid mood, anxiety, and substance use disorders.Subst Use Misuse. 2005;40(13-14):2021-41, 2043-8. doi: 10.1080/10826080500294924. Subst Use Misuse. 2005. PMID: 16282091 Review.
Cited by
-
Exploring the Link Between Attention-Deficit Hyperactivity Disorder and Cannabis Use Disorders: A Review.Med Sci Monit. 2023 May 6;29:e939749. doi: 10.12659/MSM.939749. Med Sci Monit. 2023. PMID: 37147797 Free PMC article. Review.
-
Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada.Harm Reduct J. 2021 Jun 8;18(1):61. doi: 10.1186/s12954-021-00509-0. Harm Reduct J. 2021. PMID: 34103058 Free PMC article.
-
Beyond the high: Mapping patterns of use and motives for use of cannabis as medicine.Nordisk Alkohol Nark. 2021 Jun;38(3):270-292. doi: 10.1177/1455072520985967. Epub 2021 Feb 25. Nordisk Alkohol Nark. 2021. PMID: 35310614 Free PMC article.
-
Addictive potential of novel treatments for refractory depression and anxiety.Neuropsychiatr Dis Treat. 2018 Jun 12;14:1513-1519. doi: 10.2147/NDT.S167538. eCollection 2018. Neuropsychiatr Dis Treat. 2018. PMID: 29928123 Free PMC article. Review.
-
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder.Neuropharmacology. 2023 Mar 15;226:109418. doi: 10.1016/j.neuropharm.2023.109418. Epub 2023 Jan 6. Neuropharmacology. 2023. PMID: 36623804 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical